Cowen Downgrades Adamas Pharmaceuticals (ADMS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Needham & Company Downgrades Adamas Pharmaceuticals (ADMS) to Hold
March 5, 2019 7:35 AM ESTNeedham & Company analyst Serge Belanger downgraded Adamas Pharmaceuticals (NASDAQ: ADMS) from Buy to Hold.
The analyst commented, "Gocovri ended 2018 with 4Q18 sales of $13.3MM (+25%Q/Q) via 5,730 fulfilled Rxs (+21%Q/Q) and was expected to double its market share to ~2% in... More
Mizuho Securities Downgrades Adamas Pharmaceuticals (ADMS) to Underperform
March 5, 2019 6:24 AM ESTMizuho Securities analyst Irina Koffler downgraded Adamas Pharmaceuticals (NASDAQ: ADMS) from Neutral to Underperform with a price target of $5.00 (from $11.00) after guidance was withdrawn.
we believe the launch is likely going even worse than we thoughtWe now model $58.5M in 2019... More